ons due to aerobic Gram-nega!

63 Pages·2017·2.98 MB·English

Advances in beta-lactamase inhibi1on
in difficult-to-treat infec1ons due to
7
1
0
2
aerobic Gram-nega1ve bacteria h
c
r
a
M
:
n
Tuesday 14th March 2017, 13:45–14:15 o
H
a
r
a
p
Queen Elizabeth II Conference Centre, London, UK e
r
p
f
o
e
Adverse events should be reported. Repor1ng forms and informa1on can be found at at
D
www.mhra.gov.uk/yellowcard. 6
Prescribing informa/on will be shown at the end of the presenta/on 4
ZaviceAa adverse events should also be reported to AstraZeneca on 0800 783 0033 0
0
Tygacil adverse events should also be reported to Pfizer Medical Informa1on on 01304 616161 R-
B
G
-
A
V
Z
-
P
P
This promoHonal symposium is intended for UK healthcare professionals only and is fully organised and funded by Pfizer.
Welcome and session overview
Agenda
13:45 Welcome and introducHon 7
1
0
2
Andrew Dodgson h
c
r
a
M
13:50 Epidemiology and clinical management of carbapenem-resistant Enterobacteriaceae
:
n
o
H
Andrew Dodgson a
r
a
p
e
14:00 The evolving role of beta-lactamase inhibitors in difficult-to-treat infecHons due to aerobic r
p
f
o
Gram-negaHve bacteria e
t
a
D
Ma9hew Dryden 6
4
0
0
14:10 Panel discussion and Q&A R-
B
G
-
14:15 Close A
V
Z
-
P
P
QuesHons
• QuesHons will be taken during the Q&A session a\er
7
1
0
the final presentaHon 2
h
c
r
a
M
:
n
o
H
a
r
a
p
e
r
p
f
o
e
t
a
D
6
4
0
0
-
R
B
G
-
A
V
Z
-
P
P
EvaluaHon forms
• At the end of the session, please
7
1
0
complete the evaluaHon form 2
h
c
r
a
M
inside your programme book. n:
o
H
a
r
a
p
Your feedback is important to us e
r
p
f
o
e
t
a
D
6
4
0
0
-
R
B
G
-
A
V
Z
-
P
P
Housekeeping
• Please ensure all mobile phones are switched off or
7
1
0
turned to silent 2
h
c
r
a
M
:
n
o
H
a
r
a
p
e
r
p
f
o
e
t
a
D
6
4
0
0
-
R
B
G
-
A
V
Z
-
P
P
Epidemiology and clinical management of
7
1
carbapenem-resistant Enterobacteriaceae 0
2
h
c
r
a
M
Andrew Dodgson :
n
o
H
Consultant Microbiologist, Public Health England and Central Manchester Hospitals NHS a
r
a
p
Founda/on Trust, UK e
r
p
f
o
e
Adverse events should be reported. Repor1ng forms and informa1on can be found at at
D
www.mhra.gov.uk/yellowcard. 6
Prescribing informa/on will be shown at the end of the presenta/on 4
ZaviceAa adverse events should also be reported to AstraZeneca on 0800 783 0033 0
0
Tygacil adverse events should also be reported to Pfizer Medical Informa1on on 01304 616161 R-
B
G
-
A
V
Z
-
P
P
INSERT DODGSON SLIDES HERE
Disclosures
7
1
•  Honoraria for talks: AstraZeneca, Astellas, Pfizer, Cepheid 0
2
h
c
r
a
M
:
•  Advisory boards: MSD, Basilea n
o
H
a
r
a
p
e
r
p
f
o
e
t
a
D
6
4
0
0
-
R
B
G
-
A
V
Z
-
P
P
IntroducHon
•  The WHO recently classified carbapenem-resistant Acinetobacter baumannii,
7
1
0
2
Pseudomonas aeruginosa and Enterobacteriaceae (including 3rd generaHon h
c
r
a
M
cephalosporin-resistant) as Priority 1 (criHcal*) pathogens for focussing R&D efforts n:
o
H
a
r
a
p
e
r
p
f
o
•  Today is the UK launch of Zavice\aTMq(ce\azidime—avibactam) e
t
a
D
6
4
0
0
-
R
B
G
-
•  This symposium will discuss how Zavice\aTMq may help to address some of the VA
Z
-
P
P
unmet needs in the treatment of difficult-to-treat infecHons due to aerobic
Gram-negaHve bacteria

*Mycobacteria (including M. tuberculosis), were not subjected to review for inclusion in this prioriHsaHon exercise as TB is already a globally established priority for which innovaHve
new treatments are urgently needed.
R&D, research and development; WHO, World Health OrganizaHon.
WHO. Global priority list of anHbioHc-resistant bacteria to guide research, discovery, and development of new anHbioHcs. Available at: hgp://www.who.int/medicines/publicaHons/
WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf. Accessed March 2017.
Carbapenemase-producing pathogens
7
•  Carbapenem anHbioHcs have a broad-spectrum of acHvity1 1
0
2
h
c
Ø  Currently o\en considered anHbioHcs of choice for the treatment of serious infecHons caused by ar
M
:
ESBL-producing organisms n
o
H
a
r
•  Pathogens producing carbapenemases, however, are of increasing concern2 pa
e
r
p
f
Ø  Also known as carbapenem-hydrolysing enzymes, carbapenemases are β-lactamases capable of inacHvaHng o
e
t
a
all classes of β-lactam anHbioHcs (penicillins, cephalosporins, monobactams and carbapenems)2 D
6
4
0
Ø  InfecHons caused by carbapenemase-producing pathogens are difficult to treat and have a high rate 0
-
R
B
G
of mortality2 -
A
V
Z
-
•  Carbapenemases can be either2 P
P
Ø  Ambler Class A (mainly KPC) or Class D (OXA) serine β-lactamases
Ø  Ambler Class B MBL with zinc in the acHve site
ESBL, extended-spectrum β-lactamase; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; OXA, oxacillinase.
1. Pitout JD. Drugs. 2010;70:313–333; 2. Queenan AM, Bush K. Clin Microbiol Rev. 2007;20:440‒458